Trials / Completed
CompletedNCT02360878
The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (actual)
- Sponsor
- Filip Krag Knop · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
We want to evaluate the impact of the EndoBarrier Gastrointestinal Liner (DJBS) on glucose metabolism as well as gut and pancreatic hormone secretion.
Detailed description
Duodenal-jejunal bypass sleeve (DJBS) is being developed for the treatment of obesity, and initial clinical outcomes suggest that this minimally invasive endoscopic technique potentially has beneficial effects on type 2 diabetes also. However, the mechanisms behind the antidiabetic effects of the procedure remain unknown. We want to elucidate how the DJBS might change postprandial secretion of gut and pancreatic hormones.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | EndoBarrier Gastrointestinal Liner | Implantation with the EndoBarrier |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2017-06-01
- Completion
- 2017-07-01
- First posted
- 2015-02-11
- Last updated
- 2017-08-10
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02360878. Inclusion in this directory is not an endorsement.